ID

14372

Description

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00512863

Link

https://clinicaltrials.gov/show/NCT00512863

Keywords

Versions (1)
  1. 4/12/16 4/12/16 -
Copyright Holder

CC BY-NC 3.0

Uploaded on

April 12, 2016

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Asthma NCT00512863

English

Eligibility Asthma NCT00512863

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00512863
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
documented history of refractory asthma, as defined by the american thoracic society,31 defined as 1 major and at least 2 minor criteria
Description

refractory asthma

Data type

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0205269
actual or documented history of reversible airway obstruction
Description

reversible airway obstruction

Data type

boolean

Alias
UMLS CUI [1,1]
C0001883
UMLS CUI [1,2]
C0205343
baseline fev1 of 40% − 80% of the predicted for height, age, and sex at screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist
Description

fev1

Data type

boolean

Alias
UMLS CUI [1,1]
C0748133
UMLS CUI [1,2]
C2599594
history of at least 1 asthma exacerbation leading to oral, iv or im corticosteroid or er/urgent care center visit or hospitalization within the past year prior to screening. this asthma exacerbation should not have been within 30 days prior to screening
Description

asthma exacerbation

Data type

boolean

Alias
UMLS CUI [1,1]
C0349790
UMLS CUI [1,2]
C0040223
UMLS CUI [2]
C4039704
UMLS CUI [3]
C2065041
UMLS CUI [4]
C0583237
UMLS CUI [5]
C0019993
adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits
Description

organ function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
Description

injection compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C1533685
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [copd], interstitial lung disease, pulmonary fibrosis) other than asthma
Description

lung diseases

Data type

boolean

Alias
UMLS CUI [1]
C0024115
current treatment for corticosteroid-resistant asthma (e.g., methotrexate [mtx], cyclosporine, gold salts, troleandomycin, immune globulin intravenous [igiv], mycophenolate mofetil)
Description

corticosteroid resistant asthma

Data type

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C0001617
UMLS CUI [1,3]
C0332325
UMLS CUI [1,4]
C0087111
history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma −
Description

history of cancer

Data type

boolean

Alias
UMLS CUI [1]
C2735088
UMLS CUI [2]
C0007117
UMLS CUI [3]
C0553723
in-situ of the cervix.
Description

in-situ of the cervix

Data type

boolean

Alias
UMLS CUI [1]
C0851140
history of listeria, human immunodeficiency virus (hiv), chronic or active hepatitis b, an immunodeficiency syndrome, central nervous system (cns) demyelinating disease or active tb
Description

listeria, hiv, hepatitis b, immunodeficiency syndrome, cns demyelinating disease or active tb

Data type

boolean

Alias
UMLS CUI [1]
C0023859
UMLS CUI [2]
C0019682
UMLS CUI [3]
C0019163
UMLS CUI [4]
C0011303
UMLS CUI [5]
C0041296
females who are pregnant or will not discontinue breast-feeding.
Description

pregnancy or lactation

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
subject with a history of clinically significant drug or alcohol abuse in the last year
Description

drug or alcohol abuse

Data type

boolean

Alias
UMLS CUI [1]
C0038586
subjects with a poorly controlled medical condition.
Description

poorly controlled medical condition

Data type

boolean

Alias
UMLS CUI [1]
C0009488
abnormal, clinically significant screening laboratory and other analyses (including ecg).
Description

abnormal laboratory values

Data type

boolean

Alias
UMLS CUI [1]
C1254595
subjects with any prior exposure to tysabri® (natalizumab)
Description

prior exposure to tysabri

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C1172734
prior treatment with any tnf antagonist, including adalimumab
Description

prior treatment with any tnf antagonist, including adalimumab

Data type

boolean

Alias
UMLS CUI [1,1]
C1122087
UMLS CUI [1,2]
C1514463
Back to the top of the page

Similar models

Eligibility Asthma NCT00512863

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00512863
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
refractory asthma
Item
documented history of refractory asthma, as defined by the american thoracic society,31 defined as 1 major and at least 2 minor criteria
boolean
C0004096 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
reversible airway obstruction
Item
actual or documented history of reversible airway obstruction
boolean
C0001883 (UMLS CUI [1,1])
C0205343 (UMLS CUI [1,2])
fev1
Item
baseline fev1 of 40% − 80% of the predicted for height, age, and sex at screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist
boolean
C0748133 (UMLS CUI [1,1])
C2599594 (UMLS CUI [1,2])
asthma exacerbation
Item
history of at least 1 asthma exacerbation leading to oral, iv or im corticosteroid or er/urgent care center visit or hospitalization within the past year prior to screening. this asthma exacerbation should not have been within 30 days prior to screening
boolean
C0349790 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C4039704 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0583237 (UMLS CUI [4])
C0019993 (UMLS CUI [5])
organ function
Item
adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits
boolean
C0678852 (UMLS CUI [1])
injection compliance
Item
subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
boolean
C1321605 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
lung diseases
Item
active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease [copd], interstitial lung disease, pulmonary fibrosis) other than asthma
boolean
C0024115 (UMLS CUI [1])
corticosteroid resistant asthma
Item
current treatment for corticosteroid-resistant asthma (e.g., methotrexate [mtx], cyclosporine, gold salts, troleandomycin, immune globulin intravenous [igiv], mycophenolate mofetil)
boolean
C0004096 (UMLS CUI [1,1])
C0001617 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,4])
history of cancer
Item
history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma −
boolean
C2735088 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0553723 (UMLS CUI [3])
in-situ of the cervix
Item
in-situ of the cervix.
boolean
C0851140 (UMLS CUI [1])
listeria, hiv, hepatitis b, immunodeficiency syndrome, cns demyelinating disease or active tb
Item
history of listeria, human immunodeficiency virus (hiv), chronic or active hepatitis b, an immunodeficiency syndrome, central nervous system (cns) demyelinating disease or active tb
boolean
C0023859 (UMLS CUI [1])
C0019682 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0011303 (UMLS CUI [4])
C0041296 (UMLS CUI [5])
pregnancy or lactation
Item
females who are pregnant or will not discontinue breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
drug or alcohol abuse
Item
subject with a history of clinically significant drug or alcohol abuse in the last year
boolean
C0038586 (UMLS CUI [1])
poorly controlled medical condition
Item
subjects with a poorly controlled medical condition.
boolean
C0009488 (UMLS CUI [1])
abnormal laboratory values
Item
abnormal, clinically significant screening laboratory and other analyses (including ecg).
boolean
C1254595 (UMLS CUI [1])
prior exposure to tysabri
Item
subjects with any prior exposure to tysabri® (natalizumab)
boolean
C0332157 (UMLS CUI [1,1])
C1172734 (UMLS CUI [1,2])
prior treatment with any tnf antagonist, including adalimumab
Item
prior treatment with any tnf antagonist, including adalimumab
boolean
C1122087 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial